Passive Immunization Against RSV Found 89% Effective in Infants

The U.S. Centers for Disease Control and Prevention (CDC) today reported that in Alaska, nirsevimab (Beyfortus™) was 89% effective in preventing RSV-associated hospitalization for infants in their first RSV season and 76% and 88% effective against medically attended illness for children in their first and second seasons, respectively.

On November 14, 2024, the CDC's MMWR 73(45);1015–1021 stated these findings support current CDC recommendations for all infants in their first RSV season to either receive nirsevimab or be protected through maternal vaccination and for children entering their second season with increased risk for severe RSV illness, including all AI/AN children, to receive nirsevimab.

According to the manufacturer, 50mg and 100mg of Beyfortus injection doses will be available for the 2024-2025 RSV season. And supply is secured for 20 countries.